2 results
Approved WMOCompleted
Cohorts A nd B :The primary objective is to evaluate the objective response rate (ORR) in patients with solid tumors harboring FGFRrearrangements or gastric cancer (including GEJ cancer) harboring FGFR2 amplifications based on independent central…
Approved WMORecruiting
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…